You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 14, 2025

CLINICAL TRIALS PROFILE FOR PFIZER-E


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Pfizer-e

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000159 ↗ Sorbinil Retinopathy Trial (SRT) Completed National Eye Institute (NEI) Phase 3 1983-08-01 To evaluate the safety and efficacy of the investigational drug sorbinil, an aldose reductase inhibitor, in preventing the development of diabetic retinopathy and neuropathy in persons with insulin-dependent diabetes.
NCT00000708 ↗ Multi-center Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis Completed National Institute of Allergy and Infectious Diseases (NIAID) N/A 1969-12-31 To compare the safety and effectiveness of fluconazole (FCZ) and amphotericin B (AMB), alone or in combination with flucytosine (FLC), as treatment for acute cryptococcal meningitis in patients who have not been treated previously or who have relapsed after a previous successful treatment. Cryptococcal meningitis is an important cause of disease and death among patients with AIDS. Usually AMB is given either alone or with FLC to patients with this infection, but these treatments are not always effective and both have toxic effects. Animal studies and preliminary studies in humans show that FCZ is active in cryptococcal meningitis and suggest that it may be less toxic than either AMB or FLC.
NCT00036270 ↗ Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed By Exemestane Completed Pfizer Phase 3 2001-08-01 To compare the effects of exemestane for 5 years versus tamoxifen and exemestane given sequentially over 5 years in the adjuvant treatment of postmenopausal women with early breast cancer. This Pfizer sponsored trial is part of an international collaboration of investigators conducting 7 similar yet independent studies in 9 countries. This study is designed to be part of the larger TEAM trial where the data from these 7 studies will be combined. A pre-specified analysis of the pooled data will be conducted.
NCT00088283 ↗ Pegaptanib Sodium Compared to Sham Injection in Patients With Recent Vision Loss Due to Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO) Completed Pfizer Phase 2 2004-05-01 Eyetech Pharmaceuticals Inc. and Pfizer, Inc. are studying an investigational drug, MacugenTM, for the possible treatment of CRVO. An investigational drug is one that has not been approved by the U.S. Food and Drug Administration (FDA). This investigational drug may slow the growth of abnormal blood vessels in the eye and may reduce tissue swelling in the eye. The purpose of this study is to compare the safety and efficacy of a Macugen™ injection to a "pretend" injection. In addition, the purpose of this study is to measure the action of the study drug in the body over a period of time and to check for the presence of the study drug in your blood (called pharmacokinetics or PK). This study will involve approximately 90 people. People who decide to participate will have an equal chance (1 in 3) to receive one of three study injections, two of which are Macugen™ and one of which is a "pretend" injection.
NCT00088283 ↗ Pegaptanib Sodium Compared to Sham Injection in Patients With Recent Vision Loss Due to Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO) Completed Eyetech Pharmaceuticals Phase 2 2004-05-01 Eyetech Pharmaceuticals Inc. and Pfizer, Inc. are studying an investigational drug, MacugenTM, for the possible treatment of CRVO. An investigational drug is one that has not been approved by the U.S. Food and Drug Administration (FDA). This investigational drug may slow the growth of abnormal blood vessels in the eye and may reduce tissue swelling in the eye. The purpose of this study is to compare the safety and efficacy of a Macugen™ injection to a "pretend" injection. In addition, the purpose of this study is to measure the action of the study drug in the body over a period of time and to check for the presence of the study drug in your blood (called pharmacokinetics or PK). This study will involve approximately 90 people. People who decide to participate will have an equal chance (1 in 3) to receive one of three study injections, two of which are Macugen™ and one of which is a "pretend" injection.
NCT00102895 ↗ A Research Study of CP-724,714 in Patients With HER2 Overexpressing Metastatic Breast Cancer Terminated Pfizer Phase 2 2005-04-01 The main purpose of this research study is to see if the study drug, named CP-724,714, can help in the treatment of certain breast cancers that have spread to other locations in the body. Other goals of this study are to measure how long it may take for the cancer to get worse (progress), to see if there are any side effects from the study drug, to check the amount of study drug in the blood at different times, and to check to see if there is any relationship between certain blood tests and how patients may respond to the study drug. About 25 subjects at 4 sites (hospitals and clinics) in Bulgaria and Russia will be involved in the trial. Participation in this study can last up to 48 weeks, depending on the participant's toleration of the study drug and the response of her tumor(s) to the study drug. All participants will receive CP-724,714, at a daily dose of 250 mg (4 pills) every 12 hours.
NCT00108433 ↗ Linezolid in the Treatment of Hemodialysis Patients With Catheter-Related Gram-Positive Bloodstream Infections Terminated Pfizer Phase 3 2005-09-01 This study will treat hemodialysis patients who have a central catheter that is thought to be infected with a specific bacteria (Gram positive bacteria).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Pfizer-e

Condition Name

Condition Name for Pfizer-e
Intervention Trials
Healthy 70
Healthy Volunteers 10
Schizophrenia 10
Hypertension 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Pfizer-e
Intervention Trials
Malnutrition 16
Breast Neoplasms 12
Diabetes Mellitus 11
Schizophrenia 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Pfizer-e

Trials by Country

Trials by Country for Pfizer-e
Location Trials
United States 590
Italy 154
India 66
Brazil 49
Canada 48
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Pfizer-e
Location Trials
California 40
Texas 39
Florida 31
New York 30
Connecticut 26
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Pfizer-e

Clinical Trial Phase

Clinical Trial Phase for Pfizer-e
Clinical Trial Phase Trials
Phase 4 47
Phase 3 39
Phase 2/Phase 3 5
[disabled in preview] 214
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Pfizer-e
Clinical Trial Phase Trials
Completed 175
Terminated 44
Recruiting 35
[disabled in preview] 59
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Pfizer-e

Sponsor Name

Sponsor Name for Pfizer-e
Sponsor Trials
Pfizer 123
Dr. Reddy's Laboratories Limited 14
Biogen 14
[disabled in preview] 40
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Pfizer-e
Sponsor Trials
Industry 250
Other 202
NIH 8
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Pfizer's Latest Advances: Clinical Trials, Market Analysis, and Projections for the mRNA-based Shingles Vaccine

Last updated: January 11, 2025

Introduction to Pfizer's mRNA-based Shingles Vaccine

Pfizer, in collaboration with BioNTech, has initiated a significant phase in the development of a new mRNA-based vaccine targeting shingles, a debilitating disease caused by the varicella-zoster virus (VZV). This initiative marks a crucial step in addressing the global need for highly effective and well-tolerated shingles vaccines.

Clinical Trials Update

Phase 1/2 Trial Initiation

In February 2023, Pfizer and BioNTech announced the start of a Phase 1/2 trial to evaluate the safety, tolerability, and immunogenicity of their mRNA vaccine candidates against shingles. This trial will enroll up to 900 healthy U.S. volunteers aged 50 through 69[1].

Vaccine Candidates and Technology

The mRNA shingles vaccine candidates utilize Pfizer's proprietary antigen technology and BioNTech's mRNA platform technology, similar to that used in their COVID-19 vaccine. These candidates encode different versions of glycoprotein E (gE) on the surface of the varicella zoster virus, a protein critical for viral replication and cell-to-cell spread[1].

Collaboration and Previous Work

This collaboration between Pfizer and BioNTech began in January 2022 and is part of their broader partnership, which also includes work on COVID-19 vaccines and a COVID-19 and influenza combination vaccine program[1].

Market Analysis

Current Market Need

Shingles affects millions of people worldwide each year, with approximately half of those who live to age 85 expected to develop the disease. The current market for shingles vaccines is significant, but there is a continuous need for vaccines that are highly effective, well tolerated, and efficient to produce globally[1].

Competitive Landscape

While there are currently approved vaccines for shingles, Pfizer and BioNTech aim to leverage mRNA technology to develop a vaccine that surpasses existing options in terms of efficacy, tolerability, and production efficiency. This could potentially disrupt the market by offering a more superior product[1].

Market Projections and Revenue Guidance

Pfizer's Overall Revenue Projections

Pfizer has provided full-year 2025 revenue guidance, anticipating revenues to be in the range of $61.0 to $64.0 billion. This includes expectations of stable performance in COVID-19 product sales, excluding non-recurring revenue items such as the $1.2 billion from Paxlovid in 2024[5].

Operational Growth and Cost Savings

Pfizer expects operational revenue growth to remain flat or increase by up to 5% from the 2024 baseline. The company has achieved significant cost savings of $4.0 billion through 2024 and anticipates an additional $500 million in savings in 2025 through its ongoing cost realignment program[5].

Impact of New Vaccine on Revenue

While the specific revenue projections for the mRNA-based shingles vaccine are not yet detailed, the introduction of a highly effective and well-tolerated vaccine could significantly contribute to Pfizer's revenue growth. Given the large and growing market for shingles vaccines, this new product has the potential to become a major revenue driver for the company.

Clinical Data and Efficacy

Glycoprotein E (gE) and Its Role

The mRNA vaccine candidates focus on encoding glycoprotein E (gE), which is crucial for the replication and spread of the varicella zoster virus. By targeting this protein, the vaccine aims to provide robust immune protection against shingles[1].

Comparison with Existing Vaccines

Existing shingles vaccines have shown varying degrees of efficacy, but the use of mRNA technology could offer superior immune response and longer-lasting protection. This could make Pfizer's vaccine a preferred choice for both healthcare providers and patients.

Expert Insights and Industry Perspective

Leveraging mRNA Technology

"mRNA technology has proven its potential in the COVID-19 pandemic, and its application in other diseases like shingles is a logical next step," said a pharmaceutical industry expert. "The efficiency and flexibility of mRNA vaccines make them an attractive option for addressing a wide range of infectious diseases."

Market Impact

"The introduction of an mRNA-based shingles vaccine could significantly impact the market by offering a more effective and tolerable option. This could lead to increased vaccination rates and better public health outcomes," noted another industry analyst.

Statistics and Data

  • Prevalence of Shingles: Approximately half of the people who live to age 85 are expected to develop shingles[1].
  • Current Market Size: Shingles affects millions of people worldwide each year, making it a substantial market for vaccine manufacturers.
  • Clinical Trial Enrollment: Up to 900 healthy U.S. volunteers aged 50 through 69 will be enrolled in the Phase 1/2 trial[1].

Key Takeaways

  • Initiation of Phase 1/2 Trial: Pfizer and BioNTech have started a Phase 1/2 trial for their mRNA-based shingles vaccine.
  • Market Need: There is a significant need for highly effective, well-tolerated, and efficiently produced shingles vaccines.
  • Revenue Projections: The new vaccine could contribute significantly to Pfizer's revenue growth, especially given the company's overall revenue guidance for 2025.
  • Clinical Efficacy: The vaccine targets glycoprotein E (gE) and aims to provide robust immune protection against shingles.
  • Industry Impact: The introduction of this vaccine could disrupt the market by offering a superior product, leading to increased vaccination rates and better public health outcomes.

FAQs

Q: What is the current status of Pfizer's mRNA-based shingles vaccine?

A: Pfizer and BioNTech have initiated a Phase 1/2 trial to evaluate the safety, tolerability, and immunogenicity of their mRNA vaccine candidates against shingles.

Q: How many participants will be enrolled in the Phase 1/2 trial?

A: The trial will enroll up to 900 healthy U.S. volunteers aged 50 through 69.

Q: What technology is being used in the development of this vaccine?

A: The vaccine utilizes Pfizer's proprietary antigen technology and BioNTech's mRNA platform technology.

Q: What is the market potential for this vaccine?

A: The vaccine has significant market potential given the large and growing need for effective shingles vaccines.

Q: How does this vaccine differ from existing shingles vaccines?

A: The mRNA-based vaccine targets glycoprotein E (gE) and aims to provide superior immune response and longer-lasting protection compared to existing vaccines.

Sources

  1. Pfizer and BioNTech Initiate Phase 1/2 Study of First mRNA-based Shingles Vaccine Program. Pfizer.
  2. Pfizer Targets Up to $64B Revenue in 2025 Amid Strategic Cost Savings. Tokenist.
  3. Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®). Arvinas.
  4. Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®). Arvinas.
  5. Pfizer Provides Full-Year 2025 Guidance and Reaffirms Full-Year 2024 Guidance. BioSpace.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.